PLASMID-IQ
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

PLASMID-IQ Trademark

Serial Number: 99128762

PLASMID-IQ is a trademark filed by CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC on April 9, 2025. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC (19 trademarks)

411 SWEDELAND ROAD
KING OF PRUSSIA, PA 19406

Entity Type: 16

Trademark Details

Filing Date

April 9, 2025

Registration Date

Not Registered

Goods & Services

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and ยท manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research

Manufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting; production of cell lines for others using lentivirus technology

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 5, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 5, 2026 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 12, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 12, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 12, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 5, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2025 NWOS
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 22, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 22, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 22, 2025 REAP
NEW APPLICATION ENTERED
Apr 9, 2025 NWAP
APPLICATION FILING RECEIPT MAILED
Apr 9, 2025 MAFR